{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T18:22:47Z","timestamp":1791138167820,"version":"4.1.0"},"reference-count":86,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1016\/j.ctrv.2011.03.006","type":"journal-article","created":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T07:48:50Z","timestamp":1305013730000},"page":"143-151","source":"Crossref","is-referenced-by-count":38,"title":["Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer"],"prefix":"10.1016","volume":"38","author":[{"given":"Javier","family":"Cortes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto J.","family":"Montero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Gl\u00fcck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2011.03.006_b0005","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.3816\/CBC.2008.s.001","article-title":"Pharmacodynamics of tubulin and tubulin-binding agents: extending their potential beyond taxanes","volume":"8","author":"Andreopoulou","year":"2008","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2011.03.006_b0010","doi-asserted-by":"crossref","first-page":"730","DOI":"10.2174\/156800907783220417","article-title":"How do microtubule-targeted drugs work? An overview","volume":"7","author":"Jordan","year":"2007","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ctrv.2011.03.006_b0015","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/iub.25","article-title":"Microtubules: a dynamic target in cancer therapy","volume":"60","author":"Pasquier","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.ctrv.2011.03.006_b0020","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1021\/ja00034a086","article-title":"Total synthesis of halichondrin B and norhalichondrin B","volume":"114","author":"Aicher","year":"1992","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.ctrv.2011.03.006_b0025","doi-asserted-by":"crossref","first-page":"14302","DOI":"10.1021\/bi991323e","article-title":"Interactions of the sponge-derived antimitotic tripeptide hemiasterlin with tubulin: comparison with dolastatin 10 and cryptophycin 1","volume":"38","author":"Bai","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2011.03.006_b0030","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1351\/pac198658050701","article-title":"Halichondrins: antitumor polyether macrolides from a marine sponge","volume":"58","author":"Hirata","year":"1986","journal-title":"Pure Appl Chem"},{"key":"10.1016\/j.ctrv.2011.03.006_b0035","first-page":"1013","article-title":"In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B","volume":"61","author":"Towle","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0040","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1158\/1535-7163.MCT-04-0345","article-title":"The primary antimitotic mechanism of action of the synthetic halichondrin E7389 is suppression of microtubule growth","volume":"4","author":"Jordan","year":"2005","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2011.03.006_b0045","first-page":"6026","article-title":"Suppression of microtubule dynamics by epothilone B is associated with mitotic arrest","volume":"63","author":"Kamath","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0050","doi-asserted-by":"crossref","first-page":"5760","DOI":"10.1158\/0008-5472.CAN-04-1169","article-title":"Induction of morphological and biochemical apoptosis following prolonged mitotic blockage by halichondrin B macrocyclic ketone analog E7389","volume":"64","author":"Kuznetsov","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0055","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1158\/1535-7163.MCT-08-0095","article-title":"Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase","volume":"7","author":"Okouneva","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2011.03.006_b0060","first-page":"275","article-title":"Antiproliferative effects of halichondrin B analog eribulin mesylate (E7389) against paclitaxel-resistant human cancer cells in vitro","volume":"48","author":"Kuznetsov","year":"2007","journal-title":"Proc Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0065","first-page":"1057","article-title":"Eribulin, a simplified ketone analog of the tubulin inhibitor halichondrin B, for the potential treatment of cancer","volume":"8","author":"Newman","year":"2007","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s00280-008-0755-1","article-title":"Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4","volume":"62","author":"Zhang","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0075","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1158\/1078-0432.CCR-08-2429","article-title":"A Phase I study of eribulin mesylate (E7389), a mechanistically novel inhibitor of microtubule dynamics, in patients with advanced solid tumors","volume":"15","author":"Goel","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0080","doi-asserted-by":"crossref","first-page":"200s","DOI":"10.1200\/jco.2005.23.16_suppl.3036","article-title":"A phase I pharmacokinetic, target validation study of the novel anti-tubulin agent E7389: a California Cancer consortium trial","volume":"23","author":"Synold","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0085","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1359-6349(08)72380-2","article-title":"A phase I study of eribulin mesylate (E7389) in patients with refractory cancers","volume":"6","author":"Minami","year":"2008","journal-title":"Eur J Cancer Suppl"},{"key":"10.1016\/j.ctrv.2011.03.006_b0090","doi-asserted-by":"crossref","first-page":"4213","DOI":"10.1158\/1078-0432.CCR-09-0360","article-title":"Phase I study of eribulin mesylate (E7389) administered once every 21 days in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0095","unstructured":"Gupta A, Mould DR, Reyderman L, Wanders J, Shuster D, Hussein Z, Jansen M. Population pharmacokinetic-pharmacodynamic (PK\/PD) analysis of safety and efficacy of eribuliin in metastatic or locally advanced breast cancer patients. Abstract presented at the 35th Congress of the European Society for Medical Oncology, Milan, Italy, 8\u201312 October, 2010."},{"key":"10.1016\/j.ctrv.2011.03.006_b0100","unstructured":"Devriese LA, Wanders J, Jenner A, Edwards G, Reyderman L, Copalu W, et al. Eribulin mesylate phamacokinetics in patients with solid tumors receiving repeated oral ketoconazole (KET). Abstract presented at the 22nd EORTC-AACR-NCI meeting, Berlin, Germany, November 16\u201319, 2010."},{"key":"10.1016\/j.ctrv.2011.03.006_b0105","doi-asserted-by":"crossref","first-page":"2582","DOI":"10.1200\/jco.2010.28.15_suppl.2582","article-title":"Eribulin mesylate pharmacokinetics in patients with hepatic impairment","volume":"28","author":"Witteveen","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0110","doi-asserted-by":"crossref","first-page":"2589","DOI":"10.1200\/jco.2010.28.15_suppl.2589","article-title":"Phase IB study of eribulin mesylate in combination with carboplatin in patients with advanced solid tumors","volume":"28","author":"Swami","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0115","doi-asserted-by":"crossref","first-page":"3922","DOI":"10.1200\/JCO.2009.25.8467","article-title":"Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine","volume":"28","author":"Cortes","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0120","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1200\/jco.2010.28.15_suppl.1081","article-title":"Efficacy and safety of eribulin in Japanese patients (pts) with advanced breast cancer","volume":"28","author":"Iwata","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0125","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1200\/JCO.2008.17.7618","article-title":"Phase II study of eribulin mesylate, a halichondrin B analog, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"27","author":"Vahdat","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/jco.2010.28.18_suppl.cra1004","article-title":"A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician\u2019s choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline, a taxane","volume":"28","author":"Twelves","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0135","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CBC.2010.n.023","article-title":"Phase III trials of eribulin mesylate (E7389) in extensively pretreated patients with locally recurrent or metastatic breast cancer","volume":"10","author":"Twelves","year":"2010","journal-title":"Clin Breast Cancer"},{"key":"10.1016\/j.ctrv.2011.03.006_b0140","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1517\/13543784.14.10.1259","article-title":"Vinflunine: a novel antitubulin agent in solid malignancies","volume":"14","author":"Bennouna","year":"2005","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0145","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.2174\/1381612013397456","article-title":"Vinflunine, a second generation novel vinca alkaloid with a distinctive pharmacological profile, now in clinical development and prospects for future mitotic blockers","volume":"7","author":"Hill","year":"2001","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.ctrv.2011.03.006_b0150","doi-asserted-by":"crossref","unstructured":"Ng JS. Vinflunine: review of a new vinca alkaloid and its potential role in oncology. J Oncol Pharm Pract 2010; Jun 28: [Epub ahead of print].","DOI":"10.1177\/1078155210373525"},{"key":"10.1016\/j.ctrv.2011.03.006_b0155","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1097\/COC.0b013e31818f2d2f","article-title":"Phase 2 study of single-agent IV vinflunine as third-line treatment of metastatic breast cancer after failure of anthracycline-\/taxane-based chemotherapy","volume":"32","author":"Fumoleau","year":"2009","journal-title":"Am J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0160","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.1043","article-title":"Preliminary results of a multicenter phase II trial of vinflunine (with trastuzumab in HER2+ pts) as first-line treatment in metastatic breast cancer","volume":"25","author":"Peacock","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0165","doi-asserted-by":"crossref","first-page":"925","DOI":"10.3109\/07357907.2010.496755","article-title":"A Phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer","volume":"28","author":"Yardley","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.ctrv.2011.03.006_b0170","doi-asserted-by":"crossref","first-page":"7825","DOI":"10.1158\/1078-0432.CCR-05-0058","article-title":"Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors","volume":"11","author":"Cunningham","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0175","doi-asserted-by":"crossref","first-page":"7807","DOI":"10.1158\/1078-0432.CCR-05-0909","article-title":"A phase I study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously daily for 5 consecutive days every 3 weeks in patients with advanced solid tumors","volume":"11","author":"Ebbinghaus","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0180","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s10637-005-6735-y","article-title":"Phase II trial of dolastatin-10 in patients with advanced breast cancer","volume":"23","author":"Perez","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0185","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1200\/JCO.2003.05.186","article-title":"Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 phosphate","volume":"21","author":"Anderson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0190","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1158\/1078-0432.CCR-04-1434","article-title":"Phase I trial of combretastatin a-4 phosphate with carboplatin","volume":"11","author":"Bilenker","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0195","first-page":"3408","article-title":"A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer","volume":"62","author":"Dowlati","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2007.25.18_suppl.14146","article-title":"Phase I evaluation of OXi4503, a vascular disrupting agent, in patients with advanced solid tumors","volume":"25","author":"Patterson","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0205","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1200\/JCO.2003.05.185","article-title":"Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results","volume":"21","author":"Rustin","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0210","doi-asserted-by":"crossref","first-page":"4428","DOI":"10.1200\/JCO.2003.12.986","article-title":"Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance imaging evidence for altered tumor blood flow","volume":"21","author":"Stevenson","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0215","article-title":"Phase I pharmacokinetic, DCE-MRI correlative study of AVE8062A, an antivascular combretastatin analogue, administered weekly for 3 weeks every 28-days","volume":"22","author":"Tolcher","year":"2003","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0220","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s10637-005-6729-9","article-title":"Cryptophycins-309, 249 and other cryptophycin analogs: preclinical efficacy studies with mouse and human tumors","volume":"23","author":"Liang","year":"2005","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0225","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1002\/ardp.200900067","article-title":"Synthesis and cytotoxicity studies of new cryptophycin analogues","volume":"342","author":"Liu","year":"2009","journal-title":"Arch Pharm (Weinheim)"},{"key":"10.1016\/j.ctrv.2011.03.006_b0230","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/annonc\/mdn060","article-title":"Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy","volume":"19","author":"Dieras","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0235","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00280-008-0869-5","article-title":"Phase I study of paclitaxel poliglumex administered weekly for patients with advanced solid malignancies","volume":"64","author":"Mita","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0240","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00280-008-0813-8","article-title":"A phase I and pharmacokinetic study of paclitaxel poliglumex and cisplatin in patients with advanced solid tumors","volume":"63","author":"Verschraegen","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0245","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1517\/13543784.17.3.423","article-title":"Ixabepilone for the treatment of solid tumors: a review of clinical data","volume":"17","author":"Denduluri","year":"2008","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0250","unstructured":"Bristol-Myers Squibb Company. Ixempra Kit (ixabepilone) prescribing information. 2007."},{"key":"10.1016\/j.ctrv.2011.03.006_b0255","doi-asserted-by":"crossref","first-page":"3407","DOI":"10.1200\/JCO.2006.09.3849","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0260","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1200\/JCO.2009.24.4244","article-title":"Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"28","author":"Sparano","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0265","doi-asserted-by":"crossref","first-page":"5210","DOI":"10.1200\/JCO.2007.12.6557","article-title":"Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0270","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1634\/theoncologist.2007-0167","article-title":"Ixabepilone: a novel antineoplastic agent with low susceptibility to multiple tumor resistance mechanisms","volume":"13","author":"Vahdat","year":"2008","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2011.03.006_b0275","unstructured":"Buzdar A, Silverman P, Kaufman PA. A Phase II study of KOS-862 (epothilone D) in anthracycline and taxane pretreated metastatic breast cancer: updated results. Abstract presented at the 28th Annual San Antonio Breast Cancer Symposium Proceedings TX, USA, 8\u201311 December, 2005."},{"key":"10.1016\/j.ctrv.2011.03.006_b0280","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1200\/jco.2006.24.18_suppl.2028","article-title":"A phase I trial of weekly combination KOS-862 (epothilone D), trastuzumab in HER-2 overexpressing malignancies","volume":"24","author":"Cortes","year":"2006","journal-title":"J Clin Oncol (Meeting Abstracts)"},{"key":"10.1016\/j.ctrv.2011.03.006_b0285","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1093\/annonc\/mdm198","article-title":"Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule","volume":"18","author":"Sessa","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0290","doi-asserted-by":"crossref","first-page":"3399","DOI":"10.1200\/JCO.2006.08.9102","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0295","first-page":"S73","article-title":"Safety and efficacy of patupilone in patients with advanced breast cancer: a phase IIa trial","volume":"100","author":"Toppmeyer","year":"2006","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2011.03.006_b0300","doi-asserted-by":"crossref","first-page":"5490","DOI":"10.1021\/bi983023n","article-title":"The coral-derived natural products eleutherobin and sarcodictyins A and B: effects on the assembly of purified tubulin with and without microtubule-associated proteins and binding at the polymer taxoid site","volume":"38","author":"Hamel","year":"1999","journal-title":"Biochemistry"},{"key":"10.1016\/j.ctrv.2011.03.006_b0305","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jmb.2008.03.026","article-title":"A unique mode of microtubule stabilization induced by peloruside A","volume":"378","author":"Huzil","year":"2008","journal-title":"J Mol Biol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0310","first-page":"653","article-title":"Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents","volume":"59","author":"Mooberry","year":"1999","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0315","first-page":"455","article-title":"Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management","volume":"6","author":"Swain","year":"2008","journal-title":"Clin Adv Hematol Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0320","unstructured":"Bristol-Myers Squibb Company. Taxol (paclitaxel) package insert. 2007."},{"key":"10.1016\/j.ctrv.2011.03.006_b0325","unstructured":"Abraxis Bioscience Inc. ABRAXANE\u00ae for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) prescribing information. 2007."},{"key":"10.1016\/j.ctrv.2011.03.006_b0330","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/annonc\/mdj100","article-title":"Novel formulations of taxanes: a review. Old wine in a new bottle?","volume":"17","author":"Hennenfent","year":"2006","journal-title":"Ann Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.ctrv.2011.03.006_b0335","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199200444-00002","article-title":"Preclinical and clinical pharmacology of vinca alkaloids","volume":"44","author":"Zhou","year":"1992","journal-title":"Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0340","doi-asserted-by":"crossref","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0345","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1517\/13543784.15.6.691","article-title":"Epothilones in the treatment of cancer","volume":"15","author":"Larkin","year":"2006","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0350","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.ejca.2008.04.018","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies","volume":"44","author":"Wolf","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2011.03.006_b0355","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00280-009-1014-9","article-title":"Phase I study of larotaxel administered as a 1-h intravenous infusion every 3-weeks to Japanese patients with advanced solid tumours","volume":"65","author":"Yamamoto","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0360","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1158\/1078-0432.CCR-08-0596","article-title":"Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-hour infusion every 3 weeks in patients with advanced solid tumors","volume":"15","author":"Mita","year":"2009","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0365","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10637-007-9034-y","article-title":"Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions","volume":"25","author":"Lin","year":"2007","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2011.03.006_b0370","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1093\/annonc\/mdn171","article-title":"A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients","volume":"19","author":"Pivot","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0375","doi-asserted-by":"crossref","first-page":"9120","DOI":"10.1200\/JCO.2005.03.0981","article-title":"Phase I dose-finding study of weekly single-agent patupilone in patients with advanced solid tumors","volume":"23","author":"Rubin","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0380","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s00280-007-0656-8","article-title":"A phase I trial of gemcitabine in combination with patupilone in patients with advanced solid tumors","volume":"62","author":"Schelman","year":"2008","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0385","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1093\/annonc\/mdp491","article-title":"Phase I study of the novel, fully synthetic epothilone sagopilone (ZK-EPO) in patients with solid tumors","volume":"21","author":"Schmid","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2011.03.006_b0390","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10549-010-1102-x","article-title":"Phase II study evaluating the efficacy and safety of sagopilone (ZK-EPO) in patients with metastatic breast cancer that has progressed following chemotherapy","volume":"123","author":"Morrow","year":"2010","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2011.03.006_b0395","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/sj.bjc.6603347","article-title":"Vinflunine: a new active drug for second-line treatment of advanced breast cancer. Results of a phase II and pharmacokinetic study in patients progressing after first-line anthracycline\/taxane-based chemotherapy","volume":"95","author":"Campone","year":"2006","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.03.006_b0405","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1038\/sj.bjc.6605650","article-title":"A Phase Ib trial of CA4P (combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer","volume":"102","author":"Rustin","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2011.03.006_b0410","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1021\/np900787p","article-title":"Pachycladins A-E, prostate cancer invasion and migration inhibitory eunicellin-based diterpenoids from the red sea soft coral Cladiella pachyclados","volume":"73","author":"Hassan","year":"2010","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ctrv.2011.03.006_b0415","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1021\/np0205452","article-title":"(Z)-sarcodictyin A, a new highly cytotoxic diterpenoid from the soft coral Bellonella albiflora","volume":"66","author":"Nakao","year":"2003","journal-title":"J Nat Prod"},{"key":"10.1016\/j.ctrv.2011.03.006_b0420","first-page":"5052","article-title":"Cell-based screen for antimitotic agents and identification of analogues of rhizoxin, eleutherobin, and paclitaxel in natural extracts","volume":"60","author":"Roberge","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0425","doi-asserted-by":"crossref","unstructured":"Wilmes A, O\u2019Sullivan D, Chan A et al. Synergistic interactions between peloruside A and other microtubule-stabilizing and destabilizing agents in cultured human ovarian carcinoma cells and murine T cells. Cancer Chemother Pharmacol 2010 [Epub ahead of print].","DOI":"10.1007\/s00280-010-1461-3"},{"key":"10.1016\/j.ctrv.2011.03.006_b0430","first-page":"1509","article-title":"In vitro and in vivo anticancer activities of synthetic (\u2212)-laulimalide, a marine natural product microtubule stabilizing agent","volume":"27","author":"Liu","year":"2007","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2011.03.006_b0435","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/jo9021265","article-title":"Peloruside B, a potent antitumor macrolide from the New Zealand marine sponge Mycale hentscheli: isolation, structure, total synthesis, and bioactivity","volume":"75","author":"Singh","year":"2010","journal-title":"J Org Chem"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211000600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737211000600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T01:01:01Z","timestamp":1637629261000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737211000600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4]]},"references-count":86,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["S0305737211000600"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2011.03.006","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2012,4]]}}}